Stockscreener 앱 받기
14.77
3.72%
-0.57
시간 외 거래:
14.77
전일 마감가:
$15.34
열려 있는:
$15.41
하루 거래량:
8.69M
Relative Volume:
1.91
시가총액:
$5.17B
수익:
-
순이익/손실:
$-277.02M
주가수익비율:
-15.83
EPS:
-0.9328
순현금흐름:
$-91.36M
1주 성능:
-6.99%
1개월 성능:
-18.40%
6개월 성능:
+9.41%
1년 성능:
+689.84%
1일 변동 폭
$14.51
$15.47
1주일 범위
$14.51
$16.64
52주 변동 폭
$1.75
$24.28
Erasca Inc Stock (ERAS) Company Profile
명칭
Erasca Inc
전화
(858) 465-6511
주소
3115 MERRYFIELD ROW, SAN DIEGO
Compare ERAS vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ERAS
Erasca Inc
|
14.77 | 5.55B | 0 | -277.02M | -91.36M | -0.9328 |
VRTX
Vertex Pharmaceuticals Inc
|
508.34 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
784.85 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
990.32 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
154.04 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
190.95 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Erasca Inc Stock (ERAS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-27 | 재개 | Mizuho | Outperform |
| 2026-01-07 | 개시 | Piper Sandler | Overweight |
| 2025-10-16 | 개시 | Stifel | Buy |
| 2025-09-03 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2025-08-18 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-26 | 개시 | Raymond James | Outperform |
| 2024-11-18 | 개시 | Jefferies | Buy |
| 2024-03-11 | 개시 | CapitalOne | Overweight |
| 2024-01-05 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-10-11 | 개시 | H.C. Wainwright | Buy |
| 2023-03-30 | 개시 | Mizuho | Buy |
| 2023-02-24 | 개시 | Goldman | Buy |
| 2023-02-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
모두보기
Erasca Inc 주식(ERAS)의 최신 뉴스
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Erasca, Inc. (ERAS) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Erasca, Inc. (ERAS) And Encourages Investors to Connect - ACCESS Newswire
ERAS Stock Slumps Nearly 40% After-Hours: Fine Print In 'Positive' Cancer Trial Reveals Treatment-Related Death - Stocktwits
Certain Common Stock of Erasca, Inc. are subject to a Lock-Up Agreement Ending on 12-SEP-2026. - marketscreener.com
Attention Long-Term Shareholders of Aardvark Therapeutics, - GlobeNewswire
Erasca Announces Multiple Presentations at the Upcoming 38th EORTC-NCI-AACR Symposium - manilatimes.net
Important Notice to Long-Term Shareholders of Erasca, Inc. - GlobeNewswire
Erasca, Inc. (NASDAQ:ERAS) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Erasca stock holds gains as FDA Fast Track boosts cancer pipeline - ad-hoc-news.de
FDA Fast Track Puts Erasca’s (ERAS) Pancreatic Bet Center Stage - Yahoo Finance
Erasca stock gains visibility as FDA fast tracks ERAS-0015 - ad-hoc-news.de
Erasca, Inc. (ERAS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Attention Long-Term Shareholders of Erasca, Inc. (NASDAQ: - GlobeNewswire
Long-Term Shareholders of Erasca, Inc. (ERAS) Are Encouraged to Contact Johnson Fistel Regarding Potential Claims - GlobeNewswire
ERASCA, INC. (NASDAQ: ERAS) SHAREHOLDER INVESTIGATION - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Encourages Erasca, Inc. (ERAS) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Should FDA Fast Track for ERAS-0015’s Pan-RAS Glue Require Action From Erasca (ERAS) Investors? - simplywall.st
Bronstein, Gewirtz & Grossman, LLC Is Investigating Erasca, Inc. (ERAS) And Encourages Stockholders to Connect - ACCESS Newswire
Erasca receives FDA fast track status for pancreatic cancer drug - investing.com
INVESTOR DEADLINE: Erasca, Inc. (ERAS) Investors with Substantial Losses Have Opportunity to Lead the Erasca Class Action Lawsuit - Eastern Progress
Erasca, Inc. (ERAS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
ERAS Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Erasca, Inc. Securities LawsuitContact The Gross Law Firm - Eastern Progress
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc.ERAS - Eastern Progress
Erasca (ERAS) Momentum: Slides 5.67% to $17.05 in the Latest Session; Immediate View: Traders Can Monitor the $16.20-$17.90 Range for the Current SessionIchimoku Kumo Twist - Vinanet
ERAS Stock Slumps Against RVMD Rally — Analyst Stays Bullish - Stocktwits
E Fund Management Co. Ltd. Invests $4.86 Million in Erasca, Inc. $ERAS - MarketBeat
Law firm probes Erasca directors for possible b... - Pluang
ERASCA, INC. (ERAS) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty - TMX Newsfile
81,900 Shares in Erasca, Inc. $ERAS Acquired by Handelsbanken Fonder AB - MarketBeat
Erasca, Inc. (ERAS) Investigation: Bronstein, Gewirtz & Grossman - The National Law Review
Stifel reiterates Buy rating on Erasca stock, $30 target By Investing.com - Investing.com Nigeria
Does Legal Scrutiny And Leadership Change Reshape The Bull Case For Erasca’s ERAS-0015 Program (ERAS)? - Sahm
Stifel reiterates Buy rating on Erasca stock, $30 target - Investing.com
Erasca (NASDAQ: ERAS) foundation to sell 8,333 shares - Stock Titan
ERAS STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Erasca (ERAS) insiders report 10.4% and 5.6% ownership stakes - Stock Titan
ERAS Maintained by B of A Securities -- Price Target Raised to $20 - GuruFocus
Bank of America Issues Positive Forecast for Erasca (NASDAQ:ERAS) Stock Price - MarketBeat
Erasca, Inc. Stock 12‑Month Price Target Raised to $23, Implies 29% Upside - TradingView
Attention Long-Term Shareholders of ARS Pharmaceuticals, - GlobeNewswire
HC Wainwright Has Negative Estimate for Erasca Q3 Earnings - MarketBeat
BofA Adjusts Price Target on Erasca to $20 From $18 - marketscreener.com
Erasca, Inc. (NASDAQ:ERAS) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Guggenheim raises Erasca stock price target to $21 on pipeline progress - Investing.com Nigeria
Erasca Awards 1.3 Million Stock Options to New President of R&D - Kalkine Media
Erasca, Inc. Stock 12‑Month Price Target Raised to $22.82, Implies 25% Upside - TradingView
Erasca, Inc. Stock 12‑Month Price Target Raised to $22.73, Implies 24% Upside - TradingView
Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers - The Manila Times
Erasca (NASDAQ:ERAS) Given New $22.00 Price Target at HC Wainwright - MarketBeat
H.C. Wainwright raises Erasca stock price target on trial progress By Investing.com - Investing.com South Africa
H.C. Wainwright raises Erasca stock price target on trial progress - Investing.com
Erasca Inc (ERAS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.88%
자본화:
|
볼륨(24시간):